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Overexpression of P-glycoprotein and glutathione S-transferase-t in
resistant non-small cell lung carcinomas of smokers
M. Volm, J. Mattern & B. Samsel
German Cancer Research Center, Institute ofExperimental Pathology, Im Neuenheimer Feld 280, D-6900 Heidelberg, Germany.
Summary Ninety-four human non-small cell lung carcinomas (NSCLC) of previously untreated patients were
analysed for the presence of P-glycoprotein (P-170) and glutathione S-transferase-n (GST-i) by means of
immunohistochemistry. The expression of P-170 and GST-ir was compared with the results of doxorubicin
resistance of the tumours in vitro and the smoking habits of the patients. A significant relationship between
smoking habits of the patients and resistance of NSCLC was found (P = 0.007). Of the 72 tumours of smokers
57 (= 79%) were resistant, whereas of the 22 tumours of non-smokers only 11 ( = 50%) showed resistance.
Identical results were obtained when the analysis was restricted to patients with epidermoid lung carcinomas
(P = 0.004). In contrast to these data, there exists no relationship between resistance and smoking for
adenocarcinomas of the lung.
Forty-two ( = 58%) out of the 72 NSCLC of smokers expressed P-170, whereas out of 22 tumours of
non-smokers only two tumours (= 9%) showed P-170 expression (P<0.0001). Similar results were obtained
with epidermoid carcinomas (P= 0.004) and adenocarcinomas (P = 0.027). Fifty ( = 69%) of 72 NSCLC of
smokers revealed expression of GST-w, whereas only nine (=41%) of 22 tumours of non-smokers showed
GST-i expression (P = 0.015). Significant correlations also exist between resistance in vitro and expression of
P-170 (P<0.0001) or expression of GST-i (P<0.0001). Furthermore, a significant relationship between both
proteins could be demonstrated (P<0.0001).
During the past few years the phenomenon of multidrug-
resistance (MDR) has been thoroughly analysed and some of
its molecular aspects clarified. The MDR-phenotype is char-
acterised by cross-resistance between hydrophobic compounds
without structural or functional similarities. The connection
between MDR and the expression of a 170 kDa membrane
glycoprotein (P-glycoprotein) has been clearly established in
different tumour models (Riordan et al., 1985). The most
direct evidence of the role of the P-glycoprotein (P-170) in
resistance has come from studies that have demonstrated that
resistance can be conferred through transfer of genetic ma-
terial encoding P-glycoprotein (Gros et al., 1986; Sugimoto &
Tsuruo, 1987). However, not all resistant tumours overex-
press P-170 and refractoriness to chemotherapy can only
partly be explained by P-170. Batist et al. (1986) described an
elevated expression of glutathione S-transferase-ic (GST-i )
in doxorubicin-resistant MCF-7 cells. Alterations in nuclear
DNA topoisomerase II (Topo II) content have been also
reported in doxorubicin-resistant P388 cells (Deffie et al.,
1989). Interestingly, Fairchild et al. (1987) observed an
overexpression of both P-170 and GST-i in doxorubicin-
resistant MCF-7 cells. This raises the question as to whether
the expression of those two proteins may be under a common
regulatory control.
In an earlier study with 160 human lung tumours (Volm et
al., 1990a) we demonstrated that there is a significant rela-
tionship between smoking and response to doxorubicin in
vitro. Carcinomas of smokers tended to be resistant more
frequently than carcinomas of non-smokers. Until now the
mechanisms for the resistance of lung tumours are unknown.
Therefore, we have analysed non-small cell lung carcinomas
(NSCLC) of previously untreated patients for the presence of
P-170 and GST-i by immunohistochemistry, a method which
we have found useful for detection of P-170 in the past with
different human tumours (Volm et al., 1988a; Schneider et
al., 1989; Bak et al., 1990). The current paper include 94
NSCLC of the earlier study (Volm et al., 1990a) because
alcohol-fixed samples used for immunostaining were only
collected in the second part of the study.
Materials and methods
Patients and tumours
Patients with previously untreated NSCLC were surgically
treated and fresh specimens of the tumours were fixed in
alcohol and thereafter embedded in paraffin. The mor-
phological classification of the bronchogenic carcinomas was
based on the WHO study (1981) and comprised 48 epider-
moid carcinomas, 34 adenocarcinomas and 12 large cell car-
cinomas. The histological classification of the tumours was
carried out by two pathologists. The age distribution of the
patients (81 men, 13 women) included one patient younger
than 40 years, 11 patients between 40 and 49 years, 36
between 50 and 59, 35 between 60 and 69, and 11 older than
70 years (Table I). All patients were staged at time of surgery
(pTNM). The classification of the stage was made according
to the guidelines of the American Joint Committee for
Cancer Staging and End Results Reporting (Carr & Moun-
tain, 1977). Of the 94 patients 16 had stage I, ten stage II,
and 68 had stage III tumours. Twenty-two of the patients
were nonsmokers and 72 smokers. Nine of the smokers
smoked one to ten cigarettes daily, twenty-four 11 to 20,
twelve 21 to 30, thirteen 31 to 40, and five more than 40
cigarettes daily. The daily level of smoking could not be
defined exactly for nine smokers.
Detection ofresistance by the short term-test
Most of the patients were treated by surgical procedures
alone, or by combined surgical and radiation therapy. For
this reason we used an in vitro test for determining the
resistance of the tumours to drugs. The short-term test for
predicting resistance to chemotherapy has been described
previously (Volm et al., 1979; Group for Sensitivity Testing
of Tumours (KSST), 1981). Its basic feature is measurement
of changes in the incorporation of radioactive nucleic acid
precursors into tumour cells after addition of cytostatics.
Briefly, the tumour cell suspensions are incubated with adria-
mycin (concentration 0.1-1I00 pgml-') for 3 h at 37'C. Sub-
sequently, 3H-uridine (concentration 2.5pC m1l') is added
during the last hour of incubation. Aliquots of the cell
suspensions are pipetted onto filter discs, the acid-soluble
radioactivity is extracted, and the incorporated activity mea-
sured by scintillation counting. Tumours were defined as
being sensitive or resistant depending whether uridine uptake
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Table I Patient characteristics (n = 94)
Clinical characteristics No. ofpatients
Age
40 1
40 49 11
50-59 36
60-69 35
70 11
Sex
male 81
female 13
Histology
Epidermoid Ca 48
Adeno Ca 34
Large cell Ca 12
Stage
I 16
II 10
III 68
Smoking habits
Non-smokers 22
Smokers 72
was inhibited by more or less than 35% respectively at a
concentration of adriamycin of 10 Lgml-I. This threshold
was based on prior clinical correlations (Volm et al., 1979;
Group for Sensitivity Testing of Tumours, 1981).
Immunohistochemistry
For detection of P-170 and GST-x the biotin-streptavidin-
peroxidase method described previously was used (Volm et
al., 1988a). Briefly, alcohol-fixed, paraffin-embedded 5pm thick sections were deparaffinised. After preincubation with
H202 (0.5%), unlabelled streptavidin, and non-immunised
normal serum (dilution 1:10, 10 min, Dianova, Hamburg,
Germany) the primary monoclonal antibodies were applied
for 16 h at 4°C in a moist chamber. For detection of P-170
the monoclonal antibody JSB-1 (10tgml-'; Sanbio, Uden,
Netherlands), for detection of glutathione S-transferase-ic a
rabbit antibody (dilution 1:2000; Satoh et al., 1985; kindly
provided by Dr P. Bannasch, German Cancer Research
Center, Heidelberg) and for detection of Topo II anti-Topo
II (1:500; kindly provided by Dr L. Liu, Baltimore, MD)
were used. The antibody against GST-ic was developed
against the rat isoenzyme GST-P (Satoh et al., 1985). Since
rat GST-P and human GST-i isoenzymes share 85% amino
acid sequence homology (Morrow et al., 1989) we conclude
that this antibody detects GST-ir in human lung cancers.
After three washing steps with PBS the cells were incubated
with biotinylated sheep anti-mouse IgG (Amersham, Braun-
schweig, Germany) for detection of P-170 and donkey anti-
rabbit IgG (Amersham) for detection of GST-7 , and Topo
II (30min, dilution: 1:50 with 5% normal human serum).
Afterwards, the streptavidin-biotinylated peroxidase complex
(Amersham, 1:100, 30min) was added. Peroxidase activity
was visualised with 3-amino-9-ethylcarbazole (5-10 min)
which gives a red-brown reaction product. Counterstaining
was performed with haematoxylin and the sections were
mounted with glycerol gelatin. Negative controls were done
omitting the primary antibodies. Endogenous peroxidase
activity of biopsy sections was quenched using 0.5% H202.
Furthermore unspecific binding sites were blocked by incuba-
tion with normal sheep serum (P-170) and normal donkey
serum (GST-ir , Topo II), respectively (dilution 1:10, 10 min,
Dianova). In addition, endogenous biotin may lead to poten-
tial problems in the application of streptavidin-based detec-
tion systems, therefore, unlabelled streptavidin (Amersham)
was preincubated to suppress endogenous biotin-activity (di-
lution 1:50, 10min). Because positive immunostaining was
not only found in malignant cell populations but also in
macrophages (Schlaifer et al., 1990) we distinguished between
tumour cells and macrophages using Mab CD68 (DAKO-
CD68, KP1, Dakopatts, Copenhagen, Denmark). As posi-
tive controls, acetone- and alcohol-fixed multidrug-resistant
CHO-cells and alcohol-fixed paraffin-embedded sections of
P-170 and GST-i positive human kidney and colon car-
cinomas were used. In addition, we used a sensitive and
resistant human myeloma cell line (8226/S; 8226/DOX40) as
negative and positive controls for P-170. Since 8226/S and
8226/DOY40-cells have identical GST-c levels, we used 8226/
DOX40 as negative controls for GST-c .
Three observers (M.V., J.M., B.S.) independently evaluated
and interpreted the results of immunohistochemical staining, without knowledge of the clinical data of each patient and
the results of the resistance test. The immunohistochemical
staining was expressed according to a semiquantitative scale
which we have previously established with a series of multi-
drug-resistant cell lines. The tumour samples were graded as
zero when there was complete absence of plasma membrane
staining or cytoplasmatic staining. The immuno-positive tu-
mour samples were graded as one-plus and two-plus accor-
ding to the degree of immunohistochemical staining of cells
in all areas of the specimens examined. The highest degree of
positivity found in any area of tissue section was recorded.
Table II Epidermoid carcinoma of the lung
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'NS = non-smoker; bS = smoker; csens = sensitive; dres = resistant;
0 = no staining; + = weakly positive, + + = strongly positive.702 M. VOLM et al.
Results
In the present study, 94 human non-small cell lung car-
cinomas (NSCLC) of previously untreated patients were
analysed for the presence of P-glycoprotein (P-170) and
glutathione S-transferase-i (GST-i ) by means of immuno-
histochemistry. Clinical data of the patients and characteris-
tics of the tumours are given in Table I. In Table II to Table
IV the immunohistochemical data are listed together with the
results of resistance of the tumours in vitro and the smoking
habits of the patients. Of the 48 patients with epidermoid
lung carcinomas, 38 were smokers and 10 non-smokers
(Table II). Of the 48 tumours, 39 ( = 81%) were resistant and
nine (= 19%) were sensitive to doxorubicin in the test.
Twenty-four tumours ( = 50%) showed positivity for P-170
and 33 (= 69%) for GST-ir
Table III Adenocarcinoma of the lung
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Of the 34 patients with adenocarcinomas, 22 were smokers
and 12 were non-smokers (Table III). Eighteen out of 34
tumours showed resistance in vitro (= 59%) whereas 16
tumours (= 41%) were sensitive. Eleven tumours (= 32%)
were positive for P-170 and 16 ( = 47%) for GST-i . All 12
patients with large cell carcinomas of the lung were smokers
(Table IV). All tumours except one showed resistance in
vitro. Nine tumours (= 75%) showed expression of P-170
and ten ( = 83%) expression of GST-c .
In order to examine whether a relationship exists between
smoking habits of patients, resistance of tumours in vitro,
and expression of P-170 or GST-7c , we analysed the data by
Fisher exact test. We found a significant relationship between
smoking habits of the patients with NSCLC and resistance in
vitro (P = 0.007) (Table V). Carcinomas of smokers were
more frequently resistant than carcinomas of non-smokers.
Of the 72 non-small cell lung carcinomas of smokers, 57
(= 79%) were resistant, whereas of the 22 tumours of non-
smokers only 11 ( = 50%) showed resistance. This relation-
ship is more apparent for the epidermoid lung carcinomas.
Of the 38 tumours of smokers, 34 (= 89%) were resistant
and of the ten tumours of non-smokers only five tumours
(= 50%) were resistant (P = 0.004). In contrast to these
data, there exists no relationship between resistance and
smoking for adenocarcinomas of the lung. This may be
expected because adenocarcinomas are said to be less fre-
quently associated with smoking than are epidermoid lung
carcinomas.
The relationship between expression of P-170 and GST-ic,
respectively and smoking habits of the patients, is also shown
in Table V. Forty-two ( = 58%) out of 72 non-small cell lung
carcinomas of smokers showed expression of P-170, whereas
out of 22 tumours of non-smokers only two ( = 9%) revealed
P-170 expression. This relationship is significant (P<0.0001).
A similar significant relationship was found for epidermoid
carcinomas (P =0.004) and adenocarcinomas (P = 0.027).
Fifty NSCLC (= 69%) of smokers out of 72 tumours
revealed strong expression of GST-ir. In contrast, only nine
( = 41%) out of 22 NSCLC of non-smokers showed GST-n
expression. The relationship between smoking habits of
the patients and overexpression of GST-7 is significant
(P = 0.015). Similar results are obtained when the analysis is
restricted to just those patients with epidermoid lung car-
cinomas and adenocarcinomas of the lung, but the results are
not significant (Table V). We found significant correlations
between resistance measured in vitro and expression of P-170
(P<0.0001) or expression of GST-(P<0.0001) (Table VI).
Moreover, we correlated the expression of P-170 and GST-in
and also found a significant relationship (P<0.0001) (Table
VII). A significant inter-relationship between P-170 or GST-ic
++
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+ +
+ +
+ +
+ +
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'NS = non-smoker; bS = smoker; Csens = sensitive; dres = resistant;
0 = no staining; + = weakly positive, + + = strongly positive.
Table IV Large cell carcinoma of the lung
Smoking In vitro Staining
No. Stage habits test P-170 GST
1 SI sa sensb 0 + +
2 III S resc 0 0
3 III S res 0 + +
4 I S res + 0
5 II S res + +
6 I S res + +
7 I S res + + +
8 III S res + + +
9 III S res + + +
10 III S res + + +
11 II S res + + + +
12 III S res ++ ++
as smoker; Isens = sensitive; cres = resistent; 0 = no staining;
+ = weakly positive; + + = strongly positive.
Table V Relationship between resistance, expression of
P-glycoprotein and glutathione S-transferase and smoking habits of
patients with lung carcinomas
Tumours Non-smokers Smokers P-value*
All tumours Sensitive 11 15 P = 0.007
Resistant 11 57
P-170 neg. 20 30 P<0.0001
P-170 pos. 2 42
GSTneg. 13 22 P=0.015
GST pos. 9 50
Epidermoid Sensitive 5 4 P = 0.004
lung carcinoma Resistant 5 34
P-170 neg. 9 15 P= 0.004
P-170 pos. 1 23
GST neg. 4 11 n.s.
GST pos. 6 27
Adenocarcinoma Sensitive 6 11 n.s.
Resistant 6 11
P-170 neg. 11 12 P= 0.027
P-170pos. 1 10
GST neg. 9 9 n.s.
GST pos. 3 13
*Fisher exact test.P-170 AND GST IN RESISTANT NSCLC OF SMOKERS 703
Table VI Relationship between resistance and P-glycoprotein or
glutathione S-transferase expression of non-small cell lung
carcinomas
Sensitive Resistant P-value*
P-170 neg. 23 27 P<0.0001
P-170pos. 3 41
GSTneg. 18 17 P<0.0001
GST pos. 8 51
*Fisher exact test.
Table VII Relationship between P-glycoprotein expression and
glutathione S-transferase expression
P-170 neg. P-170 pos. P-value*
GST negative 32 3 P<0.0001
GST positive 18 41
*Fisher exact test.
and age of the patients, the number of cigarettes smoked, the
stage or size of the tumours was not found.
The expression of topoisomerase II was also assessed
immunohistochemically. However, we did not find an asso-
ciation to either drug resistance of tumours or smoking
habits of patients (data not shown).
Discussion
The fact that exposure to chemical carcinogens results in
resistant cells is well known and has been shown again
recently during the past few years (Carr, 1987). In the present
study, we demonstrate that NSCLC of smokers are more
frequently resistant than tumours of non-smokers. Seventy-
nine per cent of the tumours of smokers were resistant,
whereas only 50% of the tumours of non-smokers revealed
resistance. These results are significant (P = 0.007). Identical
results were obtained when the analysis was restricted to
patients with epidermoid lung carcinomas. In contrast, we
found no relationship between doxorubicin-resistance in vitro
and smoking for adenocarcinomas of the lung. This may be
expected because adenocarcinomas are less frequently asso-
ciated with smoking than are epidermoid lung carcinomas
(Gould & Warren, 1989).
Until now, the mechanisms for the resistance of lung
tumours were unknown but might be multifactorial. Interest-
ingly, there exists a remarkable parallel between the bio-
chemical changes with carcinogen resistance and multidrug-
resistance. Thorgeirsson et al. (1987) and Fairchild et al.
(1987) reported that multidrug-resistance gene transcripts are
elevated in preneoplastic and neoplastic nodules in the rat
liver during carcinogenesis induced according to the protocol
of Solt-Faber (Solt & Faber, 1976). We also used a model of
chemical carcinogenesis in which only one carcinogen, N-
nitrosomorpholine, was administered and investigated wheth-
er overexpression of P-glycoprotein also takes place in hep-
atocellular carcinomas (Volm et al., 1990b). As shown by our
experiments, the overexpression of the multidrug-resistance
gene is apparent in hepatocellular carcinomas even after
withdrawal of the carcinogen. It seems that the multidrug-
resistance gene belongs to a programmed set of detoxifying
mechanisms that is also expressed during carcinogenesis and
might be important for lung tumours caused by smoking.
In the past few years several mechanisms for the develop-
ment of multidrug resistant cell lines in vitro have been
identified, for instance overexpression of P-glycoprotein (P-
170), glutathione S-transferase-c (GST-ic) and reduction of
DNA topoisomerase II (Topo II). P-170 appears to function
as a transporter which extrudes a broad spectrum of com-
pounds from the cell (Gottesman & Pastan, 1988). Gluta-
thione S-transferases represent a family of isoenzymes which
conjugate glutathione with various xenobiotics and may play
a role in detoxification. Topo II induces double strand breaks
during the DNA replication and downregulation of Topo II
activity circumvents cytotoxic effects. There are some hints
that these detoxifying systems may share common regulatory
elements. In the present study we investigated the overexpres-
sion of P-170, GST-ic and Topo II in NSCLC and its rela-
tionship to doxorubicin-resistance in vitro and smoking
habits of the patients. We found a significant relationship
between the overexpression of P-170 or GST-ir , and resis-
tance of the tumours or smoking habits of the patients
(P<0.0001). The overexpression of these proteins are more
frequent in resistant NSCLC and in tumours of smokers. In
contrast, we did not find an association of Topo II to either
drug resistance of tumours or smoking habits of the patients.
Thus, Topo II expression is not linked with resistance of
NSCLC of smokers.
In the present study, 44 out of 94 non-small cell lung
carcinomas ( = 47%) revealed an expression of P-170. Inter-
estingly, many tumours show a weak immunostaining for
P-170. We could not find differences between low levels and
higher levels of P-170 with regard to our resistance-results in
vitro. This indicates that low levels of P-170 are sufficient to
produce a resistance phenotype. This also demonstrates the
importance of very sensitive detection systems e.g. immuno-
histochemistry, for assessing P-170 expression in human
tumours. Radosevich et al. (1989) found P-170-expressing
cells in 100 out of 131 non-small cell lung carcinomas
(= 76%) by immunohistochemical techniques. Lai et al.
(1989) demonstrated a weak expression of P-glycoprotein
mRNA in 14 out of 24 lung tumours (= 58%). In contrast
to these results, other authors have only occasionally detec-
ted expression of the MDR gene in lung tumours (Cordon-
Cardo et al., 1990). We recently investigated the intrinsic and
acquired resistance of human epidermoid lung cancer xeno-
grafts grown in nude mice and found a correlation between
expression of P-170 and degree of resistance (Volm et al.,
1988b, 1989). As shown by Lai et al. (1989) expression of
MDR1 RNA of lung cancers was not significantly different
from that of corresponding normal lung tissue samples. In
own analyses we also found no differential expression of
P-170 and MDR1 RNA between normal lung tissue and lung
cancers in a limited number of probes (data not shown).
In the present study we correlated the expression of P-170
and GST-i and found a significant correlation (P<0.0001).
Cowan et al. (1986) reported that P-170 and GST-ic are both
overexpressed in doxorubicin-resistant MCF-7 cells. Burt et
al. (1988) demonstrated that transformation of rat liver cells
with v-H-ras or v-rafoncogenes results in a MDR-phenotype
and an elevated expression of the MDR-1 and the GST-i
gene. Keith et al. (1990) found a weak correlation between
expression of MDR1 and GST-i in human breast cancer
samples suggesting that common mechanisms may be in-
volved. To determine if there is an association between GST-i
and MDR1 expression in human leukaemia, Holmes et al.
(1990) have investigated their expression in haemopoietic
cells of untreated and treated patients. They found no
significant correlation in patients with myelodysplastic syn-
drome or in patients with acute myeloblastic leukaemia, but
a positive association between GST-i and MDR1 expression
in patients with chronic lymphatic leukaemia. In own experi-
ments we have observed a correlation between GST-i and
MDR1 expression in samples of human kidney carcinoma
but not in human leukaemia or in breast cancer (Efferth, T.,
Mattern, J., Volm, M; in preparation). This indicates that the
co-regulation of resistance mechanisms is not a common
feature and might be dependent on the tumour type. In fact,
other authors did not find a co-expression of P-170 and
GST-ir. Cole et al. (1990) described a doxorubicin-resistant
small-cell lung cancer cell line (H 69 AR) with elevated
activities of GST-i but without overexpression of P-170. In
earlier investigations we have analysed doxorubicin- and
daunomycin-resistant sublines of murine Sa 180 and L 1210
which were grown in vivo as ascites. In contrast to the
resistant Sa 180 tumour lines which show an overexpression
of P-170 and GST and a reduction of Topo II, the resistant
L 1210 lines shown only an overexpression of P-170 and the
levels of GST and Topo II are unchanged compared with the704 M. VOLM et al.
sensitive parental line (unpublished results). Our knowledge
is still sparse as to which factors are responsible for a regu-
luted co-expression of resistance mechanisms. The results of
this study demonstrate that a significant relationship between
P-170 and GST-ic in NSCLC exists and that the expression is
increased in resistant tumours of smokers. Further investiga-
tions concerning this point will deepen our understanding of
development of resistance of tumours by carcinogens.
The authors are grateful to Dr P. Bannasch, Dr T. Efferth and Dr
M.J. Walsh for helpful discussion, to E.W. Pommerenke for prepar-
ing the manuscript, and are indebted to Dr I. Vogt-Moykopf and Dr
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